Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 12 1109-1115, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Autoantibodies to the nuclear phosphoprotein nucleophosmin in breast cancer patients

B Brankin, TC Skaar, M Brotzman, B Trock and R Clarke
Vincent T. Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.

Nucleophosmin (NPM) is an estrogen-regulated nucleolar phosphoprotein; a substrate for phosphorylation by p34cdc2 kinase, protein kinase C, and casein kinase II; and a repressor of the transcriptional regulating activities of the YY1 and IFN regulatory factor-1 transcription factors. We have completed a pilot study to determine whether autoantibodies to NPM are present in breast cancer patients and explored the ability of these autoantibodies to predict recurrence in breast cancer patients. One hundred breast cancer patients were studied: 50 who recurred, and 50 matched for age and length of follow-up but who did not recur. Patients' sera were collected at the times of diagnosis (T1), six months before recurrence (T2), and at recurrence (T3). Recurrent and nonrecurrent patients did not differ in autoantibody levels at the times of diagnosis or recurrence. However, antiNPM autoantibody levels increase significantly between diagnosis and six months before recurrence in recurrent patients, whereas no change occurs over the comparable time period in nonrecurrent patients (repeated measures ANOVA; P = 0.041). At recurrence, the levels return to those seen at diagnosis. The greater the change in levels between T1 and T2, the greater the risk of recurrence within the next 6 months (conditional logistic regression: increase in risk for highest versus lowest tertile of change from T1 to T2; odds ratio, 3.25; 95% confidence interval, 1.04-10.18; P = 0.043). Consistent with the estrogenic/antiestrogenic regulation of the antigen in breast cancer cells, the levels of antiNPM autoantibodies are decreased 6 months before recurrence in patients treated with the antiestrogen tamoxifen (P = 0.012). The association between antiNPM levels and recurrence remained after adjustment for confounding factors. Further study of antiNPM autoantibody levels as a new and simple, intermediate serum biomarker for predicting both the timing of recurrence and monitoring response to endocrine manipulations in breast cancer patients is warranted.

This article has been cited by other articles:

				E. B. Affar, F. Gay, Y. Shi, H. Liu, M. Huarte, S. Wu, T. Collins, E. Li, and Y. Shi Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression. Mol. Cell. Biol., May 1, 2006; 26(9): 3565 - 3581. [Abstract] [Full Text] [PDF]

				W. D. DUAN-PORTER, L. CASCIOLA-ROSEN, and A. ROSEN Autoantigens: The Critical Partner in Initiating and Propagating Systemic Autoimmunity Ann. N.Y. Acad. Sci., December 1, 2005; 1062(1): 127 - 136. [Abstract] [Full Text] [PDF]

				K. B. Bouker, T. C. Skaar, R. B. Riggins, D. S. Harburger, D. R. Fernandez, A. Zwart, A. Wang, and R. Clarke Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis Carcinogenesis, September 1, 2005; 26(9): 1527 - 1535. [Abstract] [Full Text] [PDF]

				K. B. Bouker, T. C. Skaar, D. R. Fernandez, K. A. O'Brien, R. B. Riggins, D. Cao, and R. Clarke Interferon Regulatory Factor-1 Mediates the Proapoptotic but Not Cell Cycle Arrest Effects of the Steroidal Antiestrogen ICI 182,780 (Faslodex, Fulvestrant) Cancer Res., June 1, 2004; 64(11): 4030 - 4039. [Abstract] [Full Text] [PDF]

				D. B. Ulanet, M. Torbenson, C. V. Dang, L. Casciola-Rosen, and A. Rosen Unique conformation of cancer autoantigen B23 in hepatoma: A mechanism for specificity in the autoimmune response PNAS, October 14, 2003; 100(21): 12361 - 12366. [Abstract] [Full Text] [PDF]

				Z. Gu, R. Y. Lee, T. C. Skaar, K. B. Bouker, J. N. Welch, J. Lu, A. Liu, Y. Zhu, N. Davis, F. Leonessa, et al. Association of Interferon Regulatory Factor-1, Nucleophosmin, Nuclear Factor-{kappa}B, and Cyclic AMP Response Element Binding with Acquired Resistance to Faslodex (ICI 182,780) Cancer Res., June 1, 2002; 62(12): 3428 - 3437. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				K. Pulford, B. Falini, A. H. Banham, D. Codrington, H. Roberton, C. Hatton, and D. Y. Mason Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma Blood, August 15, 2000; 96(4): 1605 - 1607. [Abstract] [Full Text] [PDF]